MEDIUM confidence: 100% data completeness, but the composite (49) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Dated events from the market calendar; the “also watch” items are AI-generated observations from QScoring data. Informational only — not investment advice, and dates can change.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
AI classification of policy/regulatory sensitivity from the company's sector, industry, and business description. Exposure/sensitivity only — not a political opinion, a prediction of government action, or investment advice. As of 2026-07-10.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1.8B— | $2.1B+13.5% | $2.4B+15.4% | $2.9B+18.0% | $3.2B+12.9% |
| EPS (dil.) | $-0.35— | $0.75n/m | $0.88+17.3% | $2.21+151.1% | $1.80-18.6% |
| Free Cash Flow | $185M— | $55M-70.4% | $52M-6.0% | $475M+820.5% | $725M+52.5% |
| Gross Margin | 74.5% | 76.0%+1.5pp | 78.0%+2.0pp | 79.7%+1.7pp | 77.1%-2.5pp |
| Operating Margin | -4.5% | 7.7%+12.1pp | 7.7%-0.0pp | 17.0%+9.3pp | 16.6%-0.4pp |
| Net Margin | -3.5% | 6.8%+10.2pp | 6.9%+0.2pp | 15.0%+8.0pp | 10.8%-4.1pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Avg target $88 (last qtr, 9 analysts) → $102 (last mo, 5) (+15.5%).
Buy-rated share 78% → 76% over ~3 months (-2pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Aug 2026 | $0.95 | $1.20 | +26.7% |
| May 2026 | $0.78 | $0.76 | -2.6% |
| Feb 2026 | $0.17 | $-0.24 | -241.7% |
| Oct 2025 | $-0.15 | $0.12 | +180.0% |
| Aug 2025 | $0.86 | $1.44 | +67.2% |
| May 2025 | $0.94 | $1.13 | +20.2% |
| Feb 2025 | $0.54 | $0.92 | +70.4% |
| Oct 2024 | $0.78 | $0.91 | +16.7% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$3.2M over 180 days (0 open-market buys, 4 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
Working the DCF backward: holding the assumptions below, this is the free-cash-flow growth today's price implies over the next 10 years. It is a read on the price's embedded expectations — not a fair-value or target price.
The price implies FCF growth above the analyst consensus of 8.8%/yr (revenue basis).
Base free cash flow $417M (avg FY2023–FY2025; latest year $725M) · equity value $13.3B · levered FCF discounted at the cost of equity. Reverse DCF is illustrative, not advice.
The QScore of 49 for BioMarin Pharmaceutical Inc. suggests a neutral outlook, with the stock's short-term score of 52 slightly outpacing its long-term score of 45. The stock scores high on momentum, driven by a 21.1% return over the past year and a bullish 50-day versus 200-day moving average trend. However, it trades at a premium, with a P/E of 181.3, which weighs on its value score, while its profitability is moderate, with an ROE near 1.2% and a gross margin of 75.5%.